Each of these apparently under-treated groups—particularly the one on no APT—was older, with more frequent hypertension, diabetes, COPD, depression, and neoplasia, compared to patients prescribed DAPT involving a newer P2Y12 inhibitor (Table 1). This evidence concerns the gene P2RY12 and chronic obstructive pulmonary disease.